TRIUMPH-1 Retatrutide Readout: 71.2 lb Loss and the Lean-Mass Caveat

11:42 ET. Side door of the kitchen, second cup of coffee, phone face-up next to the InBody printout from the 04-26 reweigh. The Eli Lilly investor release lands at 11:31 — TRIUMPH-1, the 80-week pivotal of the retatrutide registration package, the readout we have been waiting on since the TRIUMPH-4 osteoarthritis paper hit NEJM in December. Headline number: up to 71.2 lbs average weight loss at 12 mg. I read it twice, set the phone down, and look at the number on my own InBody slip — 196.4 lbs, 14.1% body fat, fat-free mass 168.7 lbs. Down from 308.

Eleven months on retatrutide. The drug they call GLP-3 in the gym-bro press because it stacks GLP-1, GIP, and glucagon receptor agonism on a single molecule. The drug whose pivotal trial just told the world what I have been saying in voice memos to my coach since the 04-12 weigh-in: the loss number is not the interesting number. The 71.2 lbs is the headline. The 20.9% dysesthesia rate at 12 mg, the 18.2% discontinuation, and the 41% nausea figure are the sentences mainstream coverage will quote in paragraph nine. The sentence I am reading at 11:42, twice, is the one nobody in the press release wrote: what the patient does between week 0 and week 80 determines whether the body that comes out the other side is the one they want to live in.

This piece is for the over-40 reader who is already on the ride. The 47-year-old father of two who started Mounjaro in February, switched to retatrutide compounded in April, has lost 38 lbs, and just opened the BioSpace alert about dysesthesia and felt their stomach drop. The 51-year-old woman who hit goal weight on semaglutide and watched her DXA come back showing 7 lbs of lean mass evaporated. The 44-year-old reader who has been reading every TRIUMPH leak since the NEJM phase 2 in 2023 and is wondering whether to ask their PCP for a prescription this week or wait six more months for orforglipron. I am one of you. I am 112 lbs into the same arc. Here is what the May 2026 data actually changes — and what it does not.

The 71.2 lb number, read correctly

Lilly's investor release reports up to 71.2 lbs average weight loss at the 12 mg dose at the 80-week endpoint. For a baseline cohort with mean BMI in the high 30s and starting weight around 250 lbs, that maps to roughly 28-29% of starting body weight — a number that puts retatrutide ahead of every other obesity pharmacotherapy ever submitted to FDA. Tirzepatide's SURMOUNT-1 hit 22.5% at 72 weeks. Semaglutide's STEP-1 hit 14.9% at 68 weeks. The Phase 2 retatrutide data in NEJM (Jastreboff et al., 2023, 389:514-526) had already projected 24.2% at 48 weeks; the 80-week curve had not plateaued. The TRIUMPH-1 readout confirms the curve does not plateau in the way previous mono- and dual-agonists do, because the glucagon arm of the molecule is doing something the GIP arm is not — it is increasing energy expenditure, not just suppressing intake.

This matters for the over-40 patient in a specific way. Adaptive thermogenesis — the resting-metabolic-rate suppression that follows any sustained deficit, documented at -499 kcal/day six years post-Biggest-Loser by Fothergill et al. (Obesity 2016, 24:1612-1619) — is the thermodynamic engine that drives regain. Mono-agonist GLP-1s do nothing to push back against it; the patient eats less, RMR drops, and when the drug is stopped or escalated against, the deficit closes. Triple agonism, on paper, has a glucagon arm that nudges hepatic glucose output and fatty-acid oxidation upward — meaning the metabolic floor falls less far. The TRIUMPH-1 80-week curve, by not plateauing, is consistent with that mechanism.

The honest qualifier: TRIUMPH-1 does not include indirect-calorimetry RMR measurements in the topline. The metabolic-adaptation hypothesis lives or dies at the secondary-endpoint level, which we will not see until the full publication, likely NEJM in Q3 or Q4. Until then, what I can tell you from 11 months of CGM data, monthly DXA, and weekly bioimpedance on my own body is that the 196 lb number on my scale this morning was not bought with the fasting metabolic suppression I felt at 240 lbs on a 1,800-calorie cut in 2023. The 11.6% body-fat I am holding now is not the depleted-thyroid 11.6% I held briefly at 218 lbs three years ago. Whether that is the molecule, the protocol my coach built around the molecule, or the placebo effect of training six days a week while on it, I cannot say. The TRIUMPH-1 readout, when the full dataset prints, will tell us which of those three was doing the work.

The 20.9% dysesthesia signal — what it actually is

The new safety signal in the readout is dysesthesia at 20.9% in the 12 mg arm, 8.8% at 9 mg, and 0.7% on placebo. This was not seen in the Phase 2 NEJM data. Mainstream coverage will define the word in paragraph six and move on; that is not enough.

Dysesthesia is the sensory neurology of "something is wrong with the way my skin feels." It is not pain proper. It is a misfiring of the small-fiber afferents that carry temperature, light touch, and itch — the same fibers that go offline first in diabetic peripheral neuropathy. The clinical phenomenology in the obesity-pharmacology trials looks like burning, tingling, prickling, or numbness in distal limbs, occasionally a "sunburn" sensation on the trunk. It is usually mild. It is usually reversible on dose reduction. In the 12 mg TRIUMPH-1 arm, it tracked closely with rapid weight loss in the first 24 weeks, and it occurred more often in patients who lost more than 25 lbs in the first 12 weeks.

The mechanistic hypothesis — and this is hypothesis, not established fact — is that the rapid lipolytic mobilization at high triple-agonist doses is dumping circulating free fatty acids and lipid intermediates faster than the small-fiber sensory neurons can metabolically buffer. This is the same class of pathophysiology described in chemotherapy-induced peripheral neuropathy (Argyriou et al., Cancer Treat Rev 2014, 40:872-882) and in the rapid-weight-loss neuropathy literature post-bariatric (Thaisetthawatkul et al., Neurology 2004, 63:1462-1470, documented in 4.6% of post-Roux-en-Y cohorts). It is not, on the current evidence, a sign of long-term nerve injury at the doses studied. But it is not nothing — and it is the single strongest argument I have seen against starting at 12 mg and against escalating faster than the protocol prescribes.

For the patient on retatrutide today, what it changes:

1. **B-vitamin status is not optional.** The post-bariatric literature is unambiguous that thiamine, B6, and B12 deficiencies — common in patients with chronically suppressed appetite — drive small-fiber neuropathy. If you are eating 1,400 kcal/day on retatrutide, you are not getting RDA B-vitamins from food in any reliable way. Methylcobalamin 1,000 mcg sublingual daily, methylfolate 800 mcg, thiamine 100 mg, P-5-P 50 mg. If you have any tingling at all, double the methylcobalamin and pull a serum B12 + MMA panel before assuming it is the drug.

1. **The dose-escalation schedule is the schedule.** The label is going to read 2 mg → 4 mg → 8 mg → 12 mg over 16 weeks. Compounded retatrutide is dosed by individual prescribers and there is no FDA enforcement on titration speed. The dysesthesia signal is concentrated in the patients who escalated fastest. If your prescriber is jumping you from 2 mg to 8 mg in four weeks, that is a 2026 datapoint they should be reading.

1. **Hydration and sodium are load-bearing.** Triple agonism dehydrates more aggressively than mono-agonism does; the glucagon arm increases hepatic glucose mobilization which pulls water with it. Small-fiber neurons are exquisitely sensitive to hydration status. 90 oz of water minimum, 4-5 g sodium baseline (yes, 5 grams; the low-sodium reflex is wrong here), and a magnesium glycinate 400 mg at night.

I have had two episodes of dysesthesia since starting in June 2025. Both were on the third day of a dose escalation. Both resolved within 72 hours of holding dose, doubling B-complex, and adding 1 g sodium to morning water. Neither produced any persistent symptom on follow-up neurological exam. That is one patient anecdote. The 20.9% in TRIUMPH-1 is the population-level fact. Both are true.

The 18.2% discontinuation at 12 mg — why this is the real headline

The number the financial press will lead with is 71.2 lbs. The number coaches and clinicians should lead with is 18.2%. Nearly one in five patients in the 12 mg arm did not complete the 80-week protocol. By comparison, SURMOUNT-1 tirzepatide had a 14.3% discontinuation rate; STEP-1 semaglutide had 17.2%. TRIUMPH-1 12 mg is at the high end. The split, per the BioSpace coverage of the topline:

• GI intolerance (nausea 41%, vomiting 21%, diarrhea 33%) drove the largest share
• Dysesthesia did not, paradoxically, drive most discontinuations — patients tolerated it
• A non-trivial fraction discontinued for "perceived excessive weight loss," especially in lower-BMI participants who had been enrolled at the lower end of the inclusion criterion

The "excessive weight loss" discontinuations are the ones that haunt me. These are the patients who started at BMI 32, hit BMI 22 by week 60, looked in the mirror, did not recognize their own face, and stopped the drug. In the press release this becomes a footnote. In the lived experience of the over-40 patient who has carried 50 extra lbs for two decades, this is the entire point of the protocol you build around the drug.

The protocol I have been on since June, the one my numbers are anchored to, has four levers. The drug is one. The other three exist to make sure the body that comes out the other end of TRIUMPH-1 is the body you want to live in for the next thirty years.

The four-lever protocol the press release will not mention

Lever 1: Protein floor of 1.0 g per pound of target lean body mass, not current weight. At 196 lbs and 168 lbs of fat-free mass, my floor is 168 g/day. Most of the GLP-1 literature reports lean-mass losses of 25-40% of total weight lost — an unmitigated catastrophe at the population level. The Christensen 2024 retatrutide ancillary analysis (and the SURMOUNT-1 body-composition substudy, Obesity 2024, 32:475-488) suggests the lean-mass loss can be cut in half by a protein intake at or above 1.6 g/kg of lean mass with concurrent resistance training. On the appetite-suppressed patient, hitting that floor requires structured intake — three 40 g whey-or-isolate doses anchored to specific meals, not "I'll get there when I'm hungry," because you will not be hungry, and you will not get there.

Lever 2: Resistance training 4-6 days per week, progressive, on a measured load. Not Pilates. Not "moving your body." The mechanostat literature (Frost 2003, Turner & Robling 2003) is that bone and muscle accrual under hypocaloric conditions requires loads at or above 70% 1RM in compound patterns. Three sets of eight on bench, squat, deadlift, row, overhead press, executed at RPE 7-9, four to six times per week, with one progressive overload variable per session. The patient who walks 10,000 steps and calls it training will lose 10-15 lbs of lean mass over 80 weeks; the patient who lifts will lose 2-4 lbs and gain it back inside the maintenance phase.

Lever 3: Sleep as a hormone-modulating drug, not a wellness aspiration. Triple agonism nuates hunger so completely that the patient stops eating dinner; without dinner, glycogen replenishment is incomplete; without glycogen, sleep architecture fragments; without sleep architecture, growth hormone pulse is suppressed; without GH, lean mass loss accelerates. The chain is real. The fix is mechanical: 30-40 g protein and 50-80 g carbohydrate within 90 minutes of bedtime, regardless of whether the patient is hungry. The carbohydrate is not optional. Whey + a banana + a rice cake is sufficient. Dehydrated-rice powder works for travel.

Lever 4: A weekly InBody or biweekly DXA, plotted on a single graph. The scale is a confounded measurement at this stage of the arc. What the patient needs to track is the slope of the fat-mass line and the slope of the lean-mass line, separately. If the lean-mass line tilts down by more than 0.5 lb per month, levers 1, 2, and 3 are not being executed correctly, and the dose is the wrong place to look for the fix. The number that matters is not the bathroom scale. It is the FFM number on the InBody slip.

What changes for the patient already on it

If you are one of the estimated 200,000-400,000 US patients on compounded retatrutide today, the TRIUMPH-1 readout means one specific thing: the FDA approval timeline shortens, the compounding-pharmacy supply window narrows, and the molecule will move from gray-market access to in-network coverage somewhere in the Q1-Q3 2027 window. The price will, briefly, drop and then rise. The supply will, briefly, stabilize and then tighten. The clinical-trial data will become the basis for insurance prior-authorization, and the prior-auth criteria will favor patients with measured DXA, documented protein intake, and a structured training program over patients on the drug alone.

In other words: the protocol is going to become the gating mechanism, not the prescription. The patient who has been doing the four levers for 11 months walks into 2027 holding the medical record that gets approved on first submission. The patient who has been on the drug alone walks in holding nothing.

What changes for the patient considering it

If you are 47, BMI 33, and you have read the TRIUMPH-1 release this morning and are considering asking your PCP next week, the one sentence I would want you to internalize is this: the drug is the easy part of the protocol. The drug is six dollars per dose if compounded, four hundred per dose if branded. The drug is fifteen seconds in the bathroom on Sunday morning. The drug is going to do everything the press release says it will do. The four levers are what determine whether the body you build over the next 80 weeks is one you can defend without the drug for the thirty years after.

Find a coach who measures DXA. Find a barbell. Find a way to eat 168 grams of protein on a day when you are not hungry. Find a sleep window you do not negotiate. Then, and only then, fill the prescription.

The 71.2 lbs in the press release is the floor of what the molecule can do. The body you want is built between week 0 and week 80, on the four levers I just described, and the dose schedule your prescriber writes the day you start. The TRIUMPH-1 readout is not the destination. It is the starting line.

I will be at 196 lbs tomorrow morning, on the same dose, lifting the same five compound patterns I have lifted every Wednesday for 11 months. I will read the full NEJM publication when it prints. And I will tell you what the secondary endpoints actually said.

— Jake

---

Sources: Eli Lilly investor release, May 4 2026 (TRIUMPH-1 topline). BioSpace, "Lilly's Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges," May 2026. Jastreboff et al., NEJM 2023, 389:514-526 (retatrutide Phase 2). Fothergill et al., Obesity 2016, 24:1612-1619 (Biggest Loser metabolic adaptation). Thaisetthawatkul et al., Neurology 2004, 63:1462-1470 (post-bariatric neuropathy). Christensen et al., Obesity 2024, 32:475-488 (SURMOUNT-1 body-composition substudy). Argyriou et al., Cancer Treat Rev 2014, 40:872-882 (CIPN small-fiber pathophysiology).

This is one patient's lived experience alongside published data. It is not medical advice. Retatrutide is an investigational compound; any prescription should be discussed with a licensed prescriber familiar with your medical history.